Rosnilimab
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis[1][2].
Product Specifications
CAS Number
2412764-40-8
Product Name Alternative
ANB030
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rosnilimab.html
Purity
99.19
Solubility
10 mM in DMSO|H2O
Smiles
[Rosnilimab]
Molecular Weight
(146.34 kDa)
References & Citations
[1]Luu K, et al. Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial[C]//ARTHRITIS & RHEUMATOLOGY. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2023, 75: 883-884.|[2]Linggi B, et al. P0101 Phenoty of human UC colonic tissue reveals inflammatory pathway gene expression in PD-1+ conventional and regulatory T cells which overlap with those regulated by rosnilimab in a mouse model of colitis. Journal of Crohn's and Colitis, 2025, 19 (Supplement_1) : i473-i473.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
